Our results demonstrated that OVOL2 deletion promotes tumor initiation in MMTV‐PyVT mice via the regulation of FAO, thus implicating the potential clinical value of FAO inhibitors for breast cancer treatment. The gene discussed is OVOL2; the disease is neoplasm.